血管紧张素系统抑制剂对新诊断胶质瘤及接受化疗和/或贝伐珠单抗治疗的复发胶质母细胞瘤患者生存的影响
基于Kaiser Permanente北加州肿瘤登记库的回顾性电子病历分析,纳入1186例接受化疗的新诊断WHO 2-4级胶质瘤患者及181例接受贝伐珠单抗的复发胶质母细胞瘤患者。血管紧张素系统抑制剂暴露与更长总生存相关(HR 0.82;95% CI 0.71, 0.93;p=0.003),在低剂量贝伐珠单抗治疗的复发胶质母细胞瘤患者中尤为明显。
要点
- 接受化疗的胶质瘤患者中,血管紧张素系统抑制剂暴露与总生存改善相关(HR 0.82;95% CI 0.71, 0.93;p=0.003)。
- 贝伐珠单抗亚组中,血管紧张素系统抑制剂暴露进一步显示总生存优势(HR 0.75,95% CI 0.62, 0.90;p=0.002)。
- 复发胶质母细胞瘤接受低剂量贝伐珠单抗(AUCBEV < 3.6 mg wk/kg)者,血管紧张素系统抑制剂暴露组中位总生存99周(95% CI 44.3, 205),无暴露组55.6周(95% CI 37.7-73.7;p=0.032)。
核心结论
- 血管紧张素系统抑制剂使用与胶质瘤患者更长总生存相关。
- 在复发胶质母细胞瘤接受低剂量贝伐珠单抗治疗的患者中观察到血管紧张素系统抑制剂使用带来的进一步生存优势。
- 作者认为这些数据值得在前瞻性研究中评估将血管紧张素系统抑制剂加入低剂量贝伐珠单抗治疗以改善标准治疗结局。
研究设计与样本
- 回顾性、经IRB批准的电子病历审查,数据来自Kaiser Permanente北加州肿瘤登记库。
- 纳入新诊断WHO 2-4级胶质瘤患者1186例,评估血管紧张素系统抑制剂对总生存的影响,采用Cox比例风险模型分析。
- 另纳入接受不同剂量贝伐珠单抗的复发胶质母细胞瘤患者181例。
- 按接受细胞毒治疗、细胞毒治疗联合贝伐珠单抗、单用贝伐珠单抗及复发胶质母细胞瘤进行亚组分析。
主要发现
- 1186例接受化疗的胶质瘤患者中,血管紧张素系统抑制剂暴露改善总生存(HR 0.82;95% CI 0.71, 0.93;p=0.003)。
- 按贝伐珠单抗暴露分层,贝伐珠单抗组进一步显示总生存优势(HR 0.75,95% CI 0.62, 0.90;p=0.002)。
- 181例接受贝伐珠单抗的复发胶质母细胞瘤患者中,血管紧张素系统抑制剂暴露带来总生存优势(HR 0.649;95% CI 0.46, 0.92;p=0.016)。
- 接受低剂量贝伐珠单抗(AUCBEV < 3.6 mg wk/kg)且血管紧张素系统抑制剂暴露的患者中位总生存为99周(95% CI 44.3, 205),无血管紧张素系统抑制剂暴露者中位总生存为55.6周(95% CI 37.7-73.7;p=0.032)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given prior studies that suggest the use of angiotensin system inhibitors (ASIs) is associated with prolonged overall survival (OS) in glioblastoma (GBM) patients, we evaluated the effect of ASIs in glioma patients receiving chemotherapy and/or bevacizumab (BEV). Using retrospective IRB-approved electronic chart review of newly diagnosed WHO grade 2-4 glioma patients from the Kaiser Permanente Tumor Registry of Northern California, we evaluated the impact of ASIs on OS by Cox proportional hazard model analysis for subgroups who received cytotoxic therapy, cytotoxic therapy with BEV, or BEV alone, as well as those with recurrent GBM (rGBM). Of the 1186 glioma patients who received chemotherapy ASI exposure improved OS (HR 0.82; 95% CI 0.71, 0.93; p = 0.003). When stratified by BEV exposure, a sub-analysis revealed further OS advantage for the BEV group (HR 0.75, 95% CI 0.62, 0.90; p = 0.002). In a second cohort of 181 rGBM patients who received BEV in varying dosages, ASI exposure conferred an OS advantage (HR 0.649; 95% CI 0.46, 0.92; p = 0.016). Moreover, patients with ASI exposure who received low-dose BEV treatment (AUCBEV < 3.6 mg wk/kg) had a significantly longer OS (median = 99 weeks; 95% CI 44.3, 205) than those without ASI (median OS = 55.6 weeks; 95% CI 37.7-73.7; p = 0.032). ASI use is associated with longer OS in glioma patients. Further survival advantage with ASI use was observed in rGBM patients receiving low-dose bevacizumab. These data warrant prospective evaluation of adding ASI to low-dose BEV treatment in GBM patients to improve the outcome of standard therapies.
引用
- Levin VA, Chan J, Datta M, et al. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab. J Neurooncol. 2017. PMID: 28631191. doi:10.1007/s11060-017-2528-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。